Lilly books $12.9 billion in quarterly GLP-1 sales, guides higher
The incretin franchise anchored by tirzepatide continues to drive the company's growth, with management projecting further gains.
MH
By Maren Holt · Senior Reporter, GLP-1
Apr 30 03:00 ETSource: MarketWatch
The wire
- 01Eli Lilly reported roughly $12.9 billion in GLP-1 drug sales for the quarter and told investors it expects sales to keep rising.
- 02The scale of Lilly's incretin revenue shapes supply, pricing and contracting decisions that telehealth operators and pharmacists deal with directly.
- 03Guidance is a company projection, not a result; payer coverage, pricing pressure and competing launches can move actual volumes.
From the source
Read at marketwatch.comLilly is selling $12.9 billion of GLP-1 drugs every three months — and expects to sell even more